• Jose G Cervantes, Lourdes Mollard, Rodrigo A Gasque, Magalí Chahdi Beltrame, Marcelo E Lenz, M Eugenia Fernández, Suzuki Ichiro, Emilio G Quiñonez, and Francisco J Mattera.
• Unidad de Cirugía Hepatobiliar Compleja y Trasplante Hepático, Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina. E-mail: gabacervantes@gmail.com.
• Medicina (B Aires). 2024 Jan 1; 84 (4): 662671662-671.

IntroductionHepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related deaths worldwide. Hepatic resection is the treatment of choice for non-cirrhotic patients, while in cirrhotic individuals, the choice depends on tumor stage and liver function.MethodsIn this retrospective study conducted at Hospital El Cruce between 2015 and 2022, patients with HCC undergoing hepatic resection, both cirrhotic and non-cirrhotic, were evaluated. Morbidity, mortality, recurrence rate, and survival were analyzed.ResultsA total of 262 hepatectomies were performed, with 44 for HCC treatment. Among them, 35 were minor hepatectomies, and 9 were major hepatectomies (noncirrhotic patients). The majority were males (77%) with an average age of 58.5 years. Twenty-nine patients had cirrhosis, with hepatitis C (HCV) being the main cause in 48%, HCV with alcohol as a cofactor (21%), and alcohol alone (17%). Morbidity was 47.7%, with predominance of minor complications. Disease recurrence occurred in 59% of patients, and associated factors included tumor size and elevated AFP levels. Survival was better in cirrhotic patients compared to non-cirrhotic ones.DiscussionResults tion 5837 Hepatic resection is an effective option for treating HCC in well-selected cirrhotic and non-cirrhotic patients, with encouraging results in terms of survival and disease control. Additionally, close surveillance for early recurrence detection and timely interventions is suggested.

24 keywords...

hide…